Arcellx (ACLX) to Release Quarterly Earnings on Thursday

Arcellx (NASDAQ:ACLX) is projected to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 14th. Analysts expect Arcellx to post earnings of ($1.03) per share for the quarter.

Arcellx (NASDAQ:ACLX) last released its earnings results on Thursday, May 8th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.29). Arcellx had a negative return on equity of 35.27% and a negative net margin of 211.46%. The firm had revenue of $8.13 million during the quarter, compared to analyst estimates of $19.51 million. On average, analysts expect Arcellx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Arcellx Stock Down 1.9%

Shares of Arcellx stock opened at $70.67 on Thursday. The firm has a market cap of $3.89 billion, a price-to-earnings ratio of -23.64 and a beta of 0.28. Arcellx has a 52-week low of $47.86 and a 52-week high of $107.37. The company’s 50-day simple moving average is $67.23 and its 200-day simple moving average is $65.15.

Insider Activity

In other news, Director Kavita Patel sold 1,500 shares of the firm’s stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $67.36, for a total transaction of $101,040.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 8.35% of the company’s stock.

Institutional Trading of Arcellx

Institutional investors and hedge funds have recently made changes to their positions in the company. Empowered Funds LLC acquired a new stake in Arcellx during the first quarter worth about $1,768,000. Intech Investment Management LLC grew its holdings in shares of Arcellx by 27.7% during the 1st quarter. Intech Investment Management LLC now owns 21,967 shares of the company’s stock worth $1,441,000 after purchasing an additional 4,760 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Arcellx by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,753 shares of the company’s stock worth $1,893,000 after purchasing an additional 1,390 shares in the last quarter. 96.03% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ACLX. HC Wainwright reissued a “buy” rating and set a $115.00 target price on shares of Arcellx in a research note on Monday, June 16th. Scotiabank increased their price objective on Arcellx from $93.00 to $133.00 and gave the stock a “sector outperform” rating in a research report on Thursday, July 31st. Citigroup initiated coverage on Arcellx in a report on Tuesday, June 17th. They issued a “buy” rating and a $110.00 target price for the company. Finally, Cantor Fitzgerald raised shares of Arcellx to a “strong-buy” rating in a research note on Monday. Thirteen equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $114.31.

About Arcellx

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).